Skip Ribbon Commands
Skip to main content

Terumo Appoints Three Associates as the Newest Terumo Fellow

​Contributing to Terumo Group’s Core Technology in Diabetes Care, ME Devices and Neurovascular Treatment 

6/7/2022 - TOKYO, JAPAN

Terumo Corporation (TSE: 4543) today announced that it has appointed three associates as the newest "Terumo Fellow". Terumo instituted the Terumo Fellow program to recognize associates who have made outstanding contributions leading to innovation in healthcare, as well as promoting the advancement of technology, research, clinical, and regulatory affairs of the Terumo Group. Terumo Fellows are also nominated for their contribution to transmit Terumo's core technologies and serve as an inspiration for all associates. Since the establishment of the Terumo Fellow program in 2016, 9 associates have been appointed as a Terumo Fellow.

Terumo defines "Advancement of healthcare" and "Enhancement of patients' QOL" as its purpose. To realize the advancement of healthcare, Terumo will continue to accelerate activities in the fields of technology, research, clinical and regulatory affairs to further contribute to healthcare around the world.

Terumo Fellows

Tetsuya Ooyauchi

General Manager, Technology Coordination Office


  • Development of pen-type insulin injection needles used for diabetes treatment.
  • Development of diabetes care products, disposable medical devices, ME devices and a wide range of products.

Akio Kutsuzawa

General Manager, ME R&D, Cardiac and Vascular Company


  • Realizing commercialization and mass production of the controller of extracorporeal membrane oxygenation (ECMO) system.
  • Engaged in a wide range from elemental technology development to commercialization. Development and commercialization of many ME devices that can be used in combination with disposable medical devices. 

Joseph Gulachenski

Senior Director, R&D, MicroVention, Inc.


  • Led the development of more than 30 medical devices for neurovascular treatment.
  • Contributed to MicroVention to evolve from a "coil company" to expand beyond cerebral aneurysms to a "neurovascular company" including devices to treat ischemic stroke, carotid artery disease, and neurovascular malformations.

About Terumo

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.